Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA
Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. In late 2018,